May 8, 2024 Am I a Genus? The Amgen case and its impact on genus patenting for biologics By Ella Hilder
April 5, 2023 NIH Refuses to Employ “March-In” Rights in Petition to Lower Cancer Drug Costs By Olivia Santiago
March 13, 2023 Affordable Prescriptions for Patients Act of 2023: Congress’s Effort to Reduce the Impact of Patent Evergreening on Drug Prices By Khushbu Shah
March 7, 2023 New FDA Final Guidance May Pump the Brakes on Software Designed to Assist and Improve Doctor’s Clinical Decision Making By Avi Strauss